{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:20:31Z","timestamp":1783689631183,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"King Saud University, Riyadh, Saudi Arabia","award":["(RSP-2024 R47)."],"award-info":[{"award-number":["(RSP-2024 R47)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an important public health strategy to prevent people from the pandemic. Vaccines are a game-changing tool, it is essential to understand the adverse events after COVID-19 vaccination. This study explored the adverse events of COVID-19 Vaccination Oxford\u2013AstraZeneca, Pfizer-BioNTech, Moderna, Johnson and Johnson on Guillain\u2013Barr\u00e9 Syndrome (GBS). In this study, initially 128 documents were identified from the databases, including Pub-Med, Web of Science-Clarivate Analytics, Scopus, and Google Scholar. The articles on COVID-19 vaccination and GBs were searched using the keywords \u201cSARS-CoV-2, COVID-19, Vaccination, and Guillain Barr\u00e9 Syndrome, GBS\u201d, finally, 16 documents were included in the analysis and synthesis. After administering 1,680,042,214 doses of COVID-19 vaccines, 6177 cases were identified with 10.5 cases per million vaccine doses. A significant positive risk was found between COVID-19 vaccine administration and GBS with a risk rate of RR 1.97 (95% CI 1.26\u20133.08, p\u2009=\u20090.01). The mRNA vaccines were associated with 2076 cases, and 1,237,638,401 vaccine doses were linked with 4.47 GBS events per million vaccine doses. The first dose of the m-RNA vaccine was associated with  8.83 events per million doses compared to the second dose with 02 events per million doses. The viral-vector vaccine doses 193,535,249 were linked to 1630 GBS cases with 11.01 cases per million doses. The incidence of GBS after the first dose was 17.43 compared to 1.47 cases per million in the second dose of the viral-vector vaccine. The adverse events of the Oxford\u2013AstraZeneca vaccine were linked to 1339 cases of GBS following 167,786,902 vaccine doses, with 14.2 cases per million doses. The Oxford\u2013AstraZeneca vaccine significantly increased the risk of GBS RR: 2.96 (95% CI 2.51\u20133.48, p\u2009=\u20090.01). For the Pfizer-BioNTech vaccine, there were 7.20 cases per million doses of the vaccine, and no significant association was identified between the Pfizer-BioNTech vaccine and GBS incidence RR: 0.99 (95% CI 0.75\u20131.32, p\u2009=\u20090.96). Moderna vaccine was related with 419 cases of GBS after administering 420,420,909 doses, with 2.26 cases per million doses. However, Johnson and Johnson's vaccination was linked to 235 GBS after 60,256,913 doses of the vaccine with 8.80 cases per million doses. A significant association was seen between the risk of GBS and Ad.26.COV2. S vaccine, RR: 2.47 (95% CI 1.30\u20134.69, p\u2009&lt;\u20090.01). Overall, a significant association was seen between the COVID-19 vaccines and the risk of GBS. The incidence of GBS was higher after the first dose compared to GBS cases per million in the second dose.<\/jats:p>","DOI":"10.1038\/s41598-024-66999-7","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T11:02:04Z","timestamp":1723546924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the adverse events of Oxford\u2013AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain\u2013Barr\u00e9 Syndrome"],"prefix":"10.1038","volume":"14","author":[{"given":"Sultan Ayoub","family":"Meo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narmeen","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah Adnan","family":"Abukhalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha Sultan","family":"Meo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"20","key":"66999_CR1","first-page":"10133","volume":"27","author":"SA Meo","year":"2023","unstructured":"Meo, S. A., Aftab, S., Bayoumy, N. M. & Meo, A. S. Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths. Eur. Rev. Med. Pharmacol. Sci. 27(20), 10133\u201310143 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"66999_CR2","unstructured":"Wordometer. Coronavirus: Available at: https:\/\/www.worldometers.info\/coronavirus\/. Cited date. March 10, 2024."},{"issue":"10","key":"66999_CR3","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jiph.2023.08.008","volume":"16","author":"M Amamou","year":"2023","unstructured":"Amamou, M. & Ben-Ahmed, K. Managing the COVID-19 pandemic in thirty-two policy measures in Saudi Arabia: A mixed-methods analysis. J. Infect. Public Health. 16(10), 1650\u20131658 (2023).","journal-title":"J. Infect. Public Health."},{"issue":"7","key":"66999_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/vaccines10071120","volume":"10","author":"J Fan","year":"2022","unstructured":"Fan, J. et al. Advances in infectious disease vaccine adjuvants. Vaccines. 10(7), 1120 (2022).","journal-title":"Vaccines."},{"issue":"2","key":"66999_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/vaccines10020168","volume":"10","author":"T Al-Khlaiwi","year":"2022","unstructured":"Al-Khlaiwi, T. et al. National COVID-19 vaccine program and parent\u2019s perception to vaccinate their children: A cross-sectional study. Vaccines (Basel). 10(2), 168. https:\/\/doi.org\/10.3390\/vaccines10020168 (2022).","journal-title":"Vaccines (Basel)."},{"key":"66999_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3390\/vaccines11050985","volume":"11","author":"DH Abdel-Qader","year":"2023","unstructured":"Abdel-Qader, D. H. et al. Real-world effectiveness of four types of COVID-19 vaccines. Vaccines 11, 985 (2023).","journal-title":"Vaccines"},{"issue":"4","key":"66999_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1177\/08971900221097248","volume":"36","author":"BK Muhar","year":"2023","unstructured":"Muhar, B. K., Nehira, J., Malhotra, A. & Kotchoni, S. O. The race for COVID-19 vaccines: The various types and their strengths and weaknesses. J. Pharm. Pract. 36(4), 953\u2013966. https:\/\/doi.org\/10.1177\/08971900221097248 (2023).","journal-title":"J. Pharm. Pract."},{"issue":"6","key":"66999_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/vaccines11061114","volume":"11","author":"Y Yang","year":"2023","unstructured":"Yang, Y. & Huang, L. Neurological disorders following COVID-19 vaccination. Vaccines (Basel). 11(6), 1114. https:\/\/doi.org\/10.3390\/vaccines11061114 (2023).","journal-title":"Vaccines (Basel)."},{"issue":"9","key":"66999_CR9","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/life12091338","volume":"12","author":"G Tondo","year":"2022","unstructured":"Tondo, G., Virgilio, E., Naldi, A., Bianchi, A. & Comi, C. Safety of COVID-19 vaccines: Spotlight on neurological complications. Life. 12(9), 1338 (2022).","journal-title":"Life."},{"issue":"4","key":"66999_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/vaccines11040826","volume":"11","author":"SA Meo","year":"2023","unstructured":"Meo, S. A., ElToukhy, R. A., Meo, A. S. & Klonoff, D. C. Comparison of biological, pharmacological characteristics, indications, contraindications, efficacy, and adverse effects of inactivated whole-virus COVID-19 vaccines Sinopharm, CoronaVac, and Covaxin: An observational study. Vaccines (Basel). 11(4), 826 (2023).","journal-title":"Vaccines (Basel)."},{"key":"66999_CR11","unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations. Available at: https:\/\/ourworldindata.org\/covid-vaccinations. Cited date March 16, 2024."},{"issue":"1","key":"66999_CR12","doi-asserted-by":"publisher","first-page":"e0296669","DOI":"10.1371\/journal.pone.0296669","volume":"19","author":"M Eterafi","year":"2024","unstructured":"Eterafi, M. et al. Reported side-effects following Oxford\/AstraZeneca COVID-19 vaccine in the north-west province, Iran: A cross-sectional study. PLoS One. 19(1), e0296669 (2024).","journal-title":"PLoS One."},{"key":"66999_CR13","doi-asserted-by":"crossref","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res. Synth. Method. avr 2010; 1 (2): 97\u2011111.","DOI":"10.1002\/jrsm.12"},{"issue":"2","key":"66999_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/jrsm.1166","volume":"7","author":"MW Cheung","year":"2016","unstructured":"Cheung, M. W. & Cheung, S. F. Random-effects models for meta-analytic structural equation modeling: Review, issues, and illustrations. Res. Synth. Methods. 7(2), 140\u2013155 (2016).","journal-title":"Res. Synth. Methods."},{"issue":"12","key":"66999_CR15","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone, M. et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat. Med. 27(12), 2144\u20132153 (2021).","journal-title":"Nat. Med."},{"issue":"4","key":"66999_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8879","volume":"5","author":"KE Hanson","year":"2022","unstructured":"Hanson, K. E. et al. Incidence of Guillain-Barr\u00e9 Syndrome After COVID-19 vaccination in the vaccine safety Datalink. JAMA Netw. Open. 5(4), e228879. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.8879 (2022).","journal-title":"JAMA Netw. Open."},{"issue":"21","key":"66999_CR17","doi-asserted-by":"crossref","first-page":"e2094","DOI":"10.1212\/WNL.0000000000207847","volume":"101","author":"S Le Vu","year":"2023","unstructured":"Le Vu, S. et al. Risk of Guillain-Barr\u00e9 syndrome following COVID-19 vaccines: A nationwide self-controlled case series study. Neurology. 101(21), e2094\u2013e2102 (2023).","journal-title":"Neurology."},{"issue":"1","key":"66999_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0290879","volume":"19","author":"C Morciano","year":"2024","unstructured":"Morciano, C. et al. Post-marketing active surveillance of Guillain Barr\u00e9 Syndrome following COVID-19 vaccination in persons aged \u2265\u200912 years in Italy: A multi-database self-controlled case series study. PLoS ONE 19(1), e0290879 (2024).","journal-title":"PLoS ONE"},{"issue":"32","key":"66999_CR19","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1016\/j.vaccine.2022.06.010","volume":"40","author":"JL Walker","year":"2022","unstructured":"Walker, J. L. et al. Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform. Vaccine. 40(32), 4479\u20134487 (2022).","journal-title":"Vaccine."},{"key":"66999_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40261-022-01164-4","volume":"42","author":"M Atzenhoffer","year":"2022","unstructured":"Atzenhoffer, M. et al. Guillain-Barr\u00e9 syndrome associated with COVID-19 vaccines: A perspective from spontaneous report data. Clin. Drug Investig. 42, 581\u2013592 (2022).","journal-title":"Clin. Drug Investig."},{"issue":"11","key":"66999_CR21","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1111\/ene.15504","volume":"29","author":"M Garc\u00eda-Grimshaw","year":"2022","unstructured":"Garc\u00eda-Grimshaw, M. et al. Incidence of Guillain-Barr\u00e9 syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines. Eur. J. Neurol. 29(11), 3368\u20133379 (2022).","journal-title":"Eur. J. Neurol."},{"issue":"52","key":"66999_CR22","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.1016\/j.vaccine.2022.10.084","volume":"40","author":"J Osowicki","year":"2022","unstructured":"Osowicki, J. et al. Guillain-Barr\u00e9 syndrome temporally associated with COVID-19 vaccines in Victoria, Auatralia. Vaccine. 40(52), 7579\u20137585 (2022).","journal-title":"Vaccine."},{"issue":"2","key":"66999_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/brain\/awac067","volume":"146","author":"RYS Keh","year":"2023","unstructured":"Keh, R. Y. S. et al. COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: Analyses using the National Immunoglobulin Database. Brain. 146(2), 739\u2013748 (2023).","journal-title":"Brain."},{"key":"66999_CR24","doi-asserted-by":"publisher","unstructured":"Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N (2021) Association of Receipt of the Ad26.COV2. S COVID-19 Vaccine with Presumptive Guillain-Barr\u00e9 Syndrome, JAMA. 326(16), 1606\u20131613. https:\/\/doi.org\/10.1001\/jama.2021.16496.","DOI":"10.1001\/jama.2021.16496"},{"issue":"2","key":"66999_CR25","doi-asserted-by":"publisher","first-page":"e2253845","DOI":"10.1001\/jamanetworkopen.2022.53845","volume":"6","author":"WE Abara","year":"2023","unstructured":"Abara, W. E. et al. Reports of Guillain-Barr\u00e9 Syndrome After COVID-19 Vaccination in the United States. JAMA Netw Open. 6(2), e2253845 (2023).","journal-title":"JAMA Netw Open."},{"issue":"10","key":"66999_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40261-022-01191-1","volume":"42","author":"DH Abdel-Qader","year":"2022","unstructured":"Abdel-Qader, D. H. et al. Active safety surveillance of four types of COVID-19 vaccines: A national study from Jordan. Clin. Drug Investig. 42(10), 813\u2013827. https:\/\/doi.org\/10.1007\/s40261-022-01191-1 (2022).","journal-title":"Clin. Drug Investig."},{"issue":"1","key":"66999_CR27","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1038\/s41598-023-30940-1","volume":"13","author":"J Ha","year":"2023","unstructured":"Ha, J. et al. Real-world data on the incidence and risk of Guillain-Barr\u00e9 syndrome following SARS-CoV-2 vaccination: A prospective surveillance study. Sci. Rep. 13(1), 3773. https:\/\/doi.org\/10.1038\/s41598-023-30940-1 (2023).","journal-title":"Sci. Rep."},{"key":"66999_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120030","volume":"430","author":"JS Koh","year":"2021","unstructured":"Koh, J. S. et al. Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines. J. Neurol. Sci. 430, 120030 (2021).","journal-title":"J. Neurol. Sci."},{"key":"66999_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068373","volume":"376","author":"X Li","year":"2022","unstructured":"Li, X. et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population-based cohort and self-controlled case series analysis. BMJ. 376, e068373 (2022).","journal-title":"BMJ."},{"key":"66999_CR30","doi-asserted-by":"crossref","unstructured":"Takuva S, Takalani A, Seocharan I (2022) Safety evaluation of the single-dose Ad26.COV2. S vaccine among healthcare workers in the Sisonke study in South Africa A phase 3b implementation trial. PLoS Med. 19, 1004024.","DOI":"10.1371\/journal.pmed.1004024"},{"key":"66999_CR31","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1038\/s41598-024-54886-0","volume":"14","author":"SA Amer","year":"2024","unstructured":"Amer, S. A. et al. Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: A multi-national survey study. Sci. Rep. 14, 4785. https:\/\/doi.org\/10.1038\/s41598-024-54886-0 (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"66999_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","volume":"18","author":"NL Bragazzi","year":"2021","unstructured":"Bragazzi, N. L. et al. Global, regional, and national burden of Guillain-Barr\u00e9 syndrome and its underlying causes from 1990 to 2019. J. Neuroinflam. 18(1), 264. https:\/\/doi.org\/10.1186\/s12974-021-02319-4 (2021).","journal-title":"J. Neuroinflam."},{"issue":"1","key":"66999_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10072-021-05662-9","volume":"43","author":"RK Garg","year":"2022","unstructured":"Garg, R. K. & Paliwal, V. K. Spectrum of neurological complications following COVID-19 vaccination. Neurol. Sci. 43(1), 3\u201340. https:\/\/doi.org\/10.1007\/s10072-021-05662-9 (2022).","journal-title":"Neurol. Sci."},{"issue":"2","key":"66999_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamaneurol.2023.5208","volume":"81","author":"AG Willison","year":"2024","unstructured":"Willison, A. G. et al. SARS-CoV-2 vaccination and neuroimmunological disease: A review. JAMA Neurol. 81(2), 179\u2013186. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5208 (2024).","journal-title":"JAMA Neurol."},{"key":"66999_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","volume":"10","author":"B Van den Berg","year":"2014","unstructured":"Van den Berg, B. et al. Guillain-Barr\u00e9 syndrome: Pathogenesis, diagnosis, treatment, and prognosis. Nat. Rev. Neurol. 10, 469\u2013482 (2014).","journal-title":"Nat. Rev. Neurol."},{"issue":"22","key":"66999_CR36","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. 384(22), 2092\u20132101. https:\/\/doi.org\/10.1056\/NEJMoa2104840 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"66999_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ncl.2013.01.005","volume":"31","author":"MM Dimachkie","year":"2013","unstructured":"Dimachkie, M. M. & Barohn, R. J. Guillain-Barr\u00e9 syndrome and variants. Neurol. Clin. 31(2), 491\u2013510. https:\/\/doi.org\/10.1016\/j.ncl.2013.01.005 (2013).","journal-title":"Neurol. Clin."},{"issue":"3","key":"66999_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12026-023-09357-5","volume":"71","author":"M Lamprinou","year":"2023","unstructured":"Lamprinou, M., Sachinidis, A., Stamoula, E., Vavilis, T. & Papazisis, G. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol. Res. 71(3), 356\u2013372 (2023).","journal-title":"Immunol. Res."},{"key":"66999_CR39","doi-asserted-by":"crossref","unstructured":"Chua SKK, Soh QY, Saffari SE, Tan EK (2022) Prognosis of Guillain-Barr\u00e9 syndrome linked to COVID-19 vaccination. Brain Sci. 12(6), 711.","DOI":"10.3390\/brainsci12060711"},{"issue":"4","key":"66999_CR40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37578","volume":"15","author":"OB Ogunjimi","year":"2023","unstructured":"Ogunjimi, O. B., Tsalamandris, G., Paladini, A., Varrassi, G. & Zis, P. Guillain-Barr\u00e9 syndrome induced by vaccination against COVID-19: A systematic review and meta-analysis. Cureus. 15(4), e37578. https:\/\/doi.org\/10.7759\/cureus.37578 (2023).","journal-title":"Cureus."},{"issue":"2","key":"66999_CR41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/brain\/awaa433","volume":"144","author":"S Keddie","year":"2021","unstructured":"Keddie, S. et al. Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome. Brain. 144(2), 682\u2013693. https:\/\/doi.org\/10.1093\/brain\/awaa433 (2021).","journal-title":"Brain."},{"issue":"1","key":"66999_CR42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13417","volume":"144","author":"L Lu","year":"2021","unstructured":"Lu, L. et al. The potential neurological effect of the COVID-19 vaccines: a review. Acta Neurol. Scand. 144(1), 3\u201312 (2021).","journal-title":"Acta Neurol. Scand."},{"issue":"4","key":"66999_CR43","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40290-022-00436-w","volume":"36","author":"T Sullivan","year":"2022","unstructured":"Sullivan, T., Nord, M., Domalik, D., Ysander, M. & Hermann, R. P. A structured methodology to assess safety signal strength and inform causality assessment. Pharmaceut. Med. 36(4), 215\u2013222. https:\/\/doi.org\/10.1007\/s40290-022-00436-w (2022).","journal-title":"Pharmaceut. Med."},{"issue":"8","key":"66999_CR44","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.vaccine.2018.01.018","volume":"36","author":"S Tafuri","year":"2018","unstructured":"Tafuri, S. et al. Systematic causality assessment of adverse events following HPV vaccines: Analysis of current data from Apulia region (Italy). Vaccine. 36(8), 1072\u20131077. https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.018 (2018).","journal-title":"Vaccine."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66999-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66999-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66999-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T11:06:01Z","timestamp":1723547161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-66999-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["66999"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-66999-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18767"}}